PITAVASTATIN MAGNESIUM

Search structure
Trade Names:
Synonyms:
Status: Approved (2017)
Entry Type: Small molecule
Molecule Category: Salt
UNII: BDS8LUQ384
Parent Compound: PITAVASTATIN

Structure
InChI Key MPAZKXHCZWDZDY-FFNUKLMVSA-L
Smile O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.[Mg+2]
InChI
InChI=1S/2C25H24FNO4.Mg/c2*26-17-9-7-15(8-10-17)24-20-3-1-2-4-22(20)27-25(16-5-6-16)21(24)12-11-18(28)13-19(29)14-23(30)31;/h2*1-4,7-12,16,18-19,28-29H,5-6,13-14H2,(H,30,31);/q;;+2/p-2/b2*12-11+;/t2*18-,19-;/m11./s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C50H46F2MgN2O8
Molecular Weight 865.22
AlogP 4.52
Hydrogen Bond Acceptor 4.0
Hydrogen Bond Donor 3.0
Number of Rotational Bond 8.0
Polar Surface Area 90.65
Molecular species ACID
Aromatic Rings 3.0
Heavy Atoms 31.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR HMG-CoA reductase inhibitor FDA

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Hyperlipidemias 4 D006949 FDA
Dyslipidemias 4 D050171 FDA

Related Entries

Scaffolds

Parent

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Skin and subcutaneous tissue disorders
34.29
Immune system disorders
22.86
Gastrointestinal disorders
17.14
Nervous system disorders
11.43
Musculoskeletal and connective tissue disorders
5.71
Respiratory, thoracic and mediastinal disorders
5.71
General disorders and administration site conditions
2.86

Cross References

Resources Reference
ChEMBL CHEMBL3989923
FDA SRS BDS8LUQ384
PubChem 25069056
SureChEMBL SCHEMBL423028
CONTENTS